These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1951335)
21. Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin. Homma K; Homma Y; Yoshida T; Ozawa H; Shiina Y; Wakino S; Hayashi K; Itoh H; Hori S J Clin Lipidol; 2015; 9(2):210-6. PubMed ID: 25911077 [TBL] [Abstract][Full Text] [Related]
22. Effect of plasma exchange with and without concomitant drug treatment on lipids and lipoproteins in patients with familial hypercholesterolemia confirmed by tissue culture. Keller C; Hailer S; Demant T; Wolfram G; Zöllner N Atherosclerosis; 1985 Nov; 57(2-3):225-34. PubMed ID: 4084356 [TBL] [Abstract][Full Text] [Related]
23. Treatment of hypercholesterolemia by chemical adsorption of lipoproteins. Yokoyama S J Clin Apher; 1988; 4(2-3):66-71. PubMed ID: 2456283 [TBL] [Abstract][Full Text] [Related]
24. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916 [TBL] [Abstract][Full Text] [Related]
25. [Comparison between treatments of severe forms of familial hypercholesterolemia by total plasma exchange and selective removal of low density lipoproteins (LDLapheresis)]. Dairou F; Rottembourg J; de Gennes JL; Assogba U; Bruckert E; Jacobs C; Truffert J Presse Med; 1988 Oct; 17(33):1679-82. PubMed ID: 2973030 [TBL] [Abstract][Full Text] [Related]
26. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703 [TBL] [Abstract][Full Text] [Related]
27. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. Zwiener RJ; Uauy R; Petruska ML; Huet BA J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996 [TBL] [Abstract][Full Text] [Related]
28. Adsorption of lipoprotein containing apolipoprotein-B through plasma separation for treatment of familial hypercholesterolemia. Odaka M; Kobayashi H; Soeda K; Murotani N; Saito Y; Nishide T; Yoshida S; Tani N; Takata S Int J Artif Organs; 1986 Sep; 9(5):343-8. PubMed ID: 3781667 [TBL] [Abstract][Full Text] [Related]
29. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis. Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129 [TBL] [Abstract][Full Text] [Related]
30. Experience with low-density lipoprotein apheresis by polyclonal and monoclonal anti-apolipoprotein B antibodies and by dextran sulfate cellulose. Riesen WF Curr Stud Hematol Blood Transfus; 1990; (57):208-19. PubMed ID: 2272202 [No Abstract] [Full Text] [Related]
31. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730 [TBL] [Abstract][Full Text] [Related]
32. Treatment of hypercholesterolemia by precipitation of lipoproteins with dextran sulfate. Antwiler GD; Dau PC; Lobdell DD J Clin Apher; 1988; 4(2-3):72-7. PubMed ID: 2456284 [TBL] [Abstract][Full Text] [Related]
33. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis. Uauy R; Zwiener RJ; Phillips MJ; Petruska ML; Bilheimer DW J Pediatr; 1992 Jun; 120(6):892-8. PubMed ID: 1593349 [TBL] [Abstract][Full Text] [Related]
34. Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia. Drouin-Chartier JP; Tremblay AJ; Bergeron J; Pelletier M; Laflamme N; Lamarche B; Couture P J Clin Apher; 2016 Aug; 31(4):359-67. PubMed ID: 26011648 [TBL] [Abstract][Full Text] [Related]
35. [Changes in serum lipids and lipoproteins in 3 cases of heterozygous familial hypercholesterolemia treated by LDL apheresis on dextran sulfate-cellulose columns]. Delplanque B; Emmerich J; Norol F; Jourdan D; Duedari N; Jacotot B Ann Med Interne (Paris); 1988; 139 Suppl 1():80-2. PubMed ID: 2470282 [TBL] [Abstract][Full Text] [Related]
36. [New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]. Thiery J; Seidel D Versicherungsmedizin; 1992 Dec; 44(6):186-92. PubMed ID: 1475888 [TBL] [Abstract][Full Text] [Related]
37. Single LDL apheresis improves serum remnant-like particle-cholesterol, C-reactive protein, and malondialdehyde-modified-low-density lipoprotein concentrations in Japanese hypercholesterolemic subjects. Kobayashi J; Katsube S; Shimoda M; Furuhashi K; Kitano S; Masuda M; Maruyama T; Shinomiya M Clin Chim Acta; 2002 Jul; 321(1-2):107-12. PubMed ID: 12031599 [TBL] [Abstract][Full Text] [Related]
38. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments. Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498 [TBL] [Abstract][Full Text] [Related]
39. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. Lappegård KT; Enebakk T; Thunhaug H; Hovland A Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831 [TBL] [Abstract][Full Text] [Related]
40. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Richter WO; Donner MG; Höfling B; Schwandt P Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]